OA12.02 Updated Antitumor Activity of Crizotinib in Patients With MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.300
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer

American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer ResearchOncology
2015English

OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Advanced Non-Small Cell Lung Cancer in Elderly Patients

Breathe
PulmonaryRespiratory Medicine
2012English

Circadian Function in Patients With Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

P2.01-44 Prognostic Value of TP53 Hot Exon Mutation in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer With ALK-rearrangement: A Brief Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy